CreativeOne Wealth LLC Acquires Shares of 10,495 Hims & Hers Health, Inc. $HIMS

CreativeOne Wealth LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 10,495 shares of the company’s stock, valued at approximately $523,000.

Other institutional investors have also made changes to their positions in the company. Smartleaf Asset Management LLC lifted its stake in Hims & Hers Health by 15.7% during the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock worth $49,000 after purchasing an additional 227 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the period. True Vision MN LLC lifted its position in shares of Hims & Hers Health by 3.6% in the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock worth $467,000 after buying an additional 328 shares during the last quarter. WealthPlan Investment Management LLC boosted its holdings in shares of Hims & Hers Health by 2.6% in the 2nd quarter. WealthPlan Investment Management LLC now owns 16,404 shares of the company’s stock valued at $818,000 after buying an additional 410 shares during the period. Finally, Securian Asset Management Inc. grew its position in shares of Hims & Hers Health by 2.8% during the 2nd quarter. Securian Asset Management Inc. now owns 14,931 shares of the company’s stock valued at $744,000 after buying an additional 411 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Up 3.6%

HIMS opened at $39.79 on Friday. Hims & Hers Health, Inc. has a 12 month low of $23.97 and a 12 month high of $72.98. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The stock has a market cap of $9.06 billion, a P/E ratio of 73.69, a P/E/G ratio of 7.92 and a beta of 2.20. The stock’s 50 day moving average price is $47.56 and its 200 day moving average price is $50.57.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. During the same quarter last year, the firm posted $0.32 EPS. The company’s revenue was up 49.2% compared to the same quarter last year. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has initiated a share repurchase plan on Monday, November 17th that permits the company to buyback $250.00 million in shares. This buyback authorization permits the company to purchase up to 3% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, November 24th. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Canaccord Genuity Group restated a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a research report on Friday, September 12th. Bank of America increased their target price on Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research report on Tuesday, November 4th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Reduce” and an average target price of $45.27.

Insider Buying and Selling

In other Hims & Hers Health news, insider Michael Chi sold 900 shares of the firm’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $58.25, for a total transaction of $52,425.00. Following the transaction, the insider owned 291,439 shares of the company’s stock, valued at approximately $16,976,321.75. This trade represents a 0.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 23,187 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $36.81, for a total transaction of $853,513.47. Following the completion of the sale, the chief financial officer directly owned 70,232 shares of the company’s stock, valued at approximately $2,585,239.92. This represents a 24.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 616,431 shares of company stock valued at $32,924,482 over the last 90 days. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.